Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2009

Open Access 01-06-2009 | Melanomas

Surgical Strategies and Histopathologic Issues in the Management of Lentigo Maligna

Authors: Jonathan R. Stretch, MBBS, DPhil, FRACS, Richard A. Scolyer, MD, FRCPA, FRCPath

Published in: Annals of Surgical Oncology | Issue 6/2009

Login to get access

Excerpt

Lentigo maligna (LM) (also termed Hutchinson’s melanotic freckle and precancerous melanosis of Dubreuilh) is a major clinical problem, particularly in individuals of European origin living in areas of high sunlight exposure, and its incidence continues to increase. LM is usually regarded as a form of melanoma-in-situ, although a distinction between different phases of LM as a melanoma precursor and in-situ melanoma has been proposed.1 The article by Moller et al. published in this issue highlights some of the important pathobiologic features of LM and the implications of its management.2 It also provides an appropriate opportunity to review some of the challenges associated with developing strategies to delineate and treat it. …
Literature
1.
Tannous ZS, Lerner LH, Duncan LM, et al. Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type. Hum Pathol. 2000;31:705–8.PubMedCrossRef
2.
Moller MG, Pappas-Politis E, Zager JS, et al. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol. DOI:10.​1245/​s10434-008-0239-x.
3.
Stante M, Giorgi V, Stanganelli I, et al. Dermoscopy for early detection of facial lentigo maligna. Br J Dermatol. 2005;152:361–4.PubMedCrossRef
4.
Chen CS, Elias M, Busam K, et al. Multimodal in vivo optical imaging, including confocal microscopy, facilitates presurgical margin mapping for clinically complex lentigo maligna melanoma. Br J Dermatol. 2005;153:1031–6.PubMedCrossRef
5.
Dalton SR, Gardner TL, Libow LF, et al. Contiguous lesions in lentigo maligna. J Am Acad Dermatol. 2005;52:859–62.PubMedCrossRef
6.
Klauder JV, Beerman H. Melanotic freckle (Hutchinson), melanose circonscrite precancereuse (Dubreuilh). AMA Arch Dermatol. 1955;71:2–10.PubMed
7.
Weyers W, Bonczkowitz M, Weyers I, et al. Melanoma in situ versus melanocytic hyperplasia in sun-damaged skin. Assessment of the significance of histopathologic criteria for differential diagnosis. Am J Dermatopathol. 1996;18:560–6.PubMedCrossRef
8.
Cohen LM. The starburst giant cell is useful for distinguishing lentigo maligna from photodamaged skin. J Am Acad Dermatol. 1996;35:962–8.PubMedCrossRef
9.
Saldanha G, Potter L, Daforno P, et al. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res. 2006;12:4499–505.PubMedCrossRef
10.
Akslen LA, Puntervoll H, Bachmann IM, et al. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res. 2008;18:29–35.PubMedCrossRef
11.
Lang J, MacKie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol. 2005;125:575–9.PubMedCrossRef
12.
Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.PubMedCrossRef
13.
Mahoney MH, Joseph M, Temple CL. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. J Surg Oncol. 2005;91:120–5.PubMedCrossRef
14.
Johnson TM, Headington JT, Baker SR, et al. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure. J Am Acad Dermatol. 1997;37:758–64.PubMedCrossRef
15.
Jeneby TT, Chang B, Bucky LP. Ultraviolet-assisted punch biopsy mapping for lentigo maligna melanoma. Ann Plast Surg. 2001;46:495–9.PubMedCrossRef
16.
Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 2000;60:1968–73.PubMed
17.
North JP, Kageshita T, Pinkel D, et al. Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J Invest Dermatol. 2008;128:2024–30.PubMedCrossRef
Metadata
Title
Surgical Strategies and Histopathologic Issues in the Management of Lentigo Maligna
Authors
Jonathan R. Stretch, MBBS, DPhil, FRACS
Richard A. Scolyer, MD, FRCPA, FRCPath
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0433-5

Other articles of this Issue 6/2009

Annals of Surgical Oncology 6/2009 Go to the issue

Hepatobiliary and Pancreatic Tumors

In Search of the Black Sheep: Is It Bevacizumab or Extended Chemotherapy?

Thoracic Oncology

Association of Clinical and Dosimetric Factors with Postoperative Pulmonary Complications in Esophageal Cancer Patients Receiving Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy Followed by Thoracic Esophagectomy

Translational Research and Biomarkers

Correlation Between Connexin 26 Expression and Poor Prognosis of Esophageal Squamous Cell Carcinoma

Breast Oncology

Residual Breast Cancer Diagnosed by MRI in Patients Receiving Neoadjuvant Chemotherapy with and Without Bevacizumab

Endocrine Tumors

Preoperative Ultrasound-Guided Tattooing Localization of Recurrences After Thyroidectomy: Safety and Effectiveness

EDUCATIONAL REVIEW– TRANSLATIONAL RESEARCH AND BIOMARKERS

Pathologic Response to Preoperative Therapy: Does It Mean What We Think It Means?